LOTEMAX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Lotemax, and when can generic versions of Lotemax launch?
Lotemax is a drug marketed by Bausch And Lomb Inc, Bausch And Lomb, and Pharmos. and is included in five NDAs. There are two patents protecting this drug.
The generic ingredient in LOTEMAX is loteprednol etabonate. There are ten drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Lotemax
A generic version of LOTEMAX was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LOTEMAX?
- What are the global sales for LOTEMAX?
- What is Average Wholesale Price for LOTEMAX?
Summary for LOTEMAX
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 5 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 63 |
| Clinical Trials: | 22 |
| Patent Applications: | 4,390 |
| Drug Prices: | Drug price information for LOTEMAX |
| Drug Sales Revenues: | Drug sales revenues for LOTEMAX |
| What excipients (inactive ingredients) are in LOTEMAX? | LOTEMAX excipients list |
| DailyMed Link: | LOTEMAX at DailyMed |
Recent Clinical Trials for LOTEMAX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Thomas Chester, OD | Phase 4 |
| Illinois College of Optometry | Early Phase 1 |
| Dr Salouti Eye Research Center | Phase 4 |
Pharmacology for LOTEMAX
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for LOTEMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | LOTEMAX | loteprednol etabonate | GEL;OPHTHALMIC | 202872-001 | Sep 28, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | OINTMENT;OPHTHALMIC | 200738-001 | Apr 15, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Bausch And Lomb Inc | LOTEMAX SM | loteprednol etabonate | GEL;OPHTHALMIC | 208219-001 | Feb 22, 2019 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LOTEMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bausch And Lomb Inc | LOTEMAX | loteprednol etabonate | GEL;OPHTHALMIC | 202872-001 | Sep 28, 2012 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Pharmos | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020841-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| Bausch And Lomb | LOTEMAX | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 020583-001 | Mar 9, 1998 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LOTEMAX
See the table below for patents covering LOTEMAX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 2205449 | ⤷ Sign Up | |
| Israel | 111402 | ⤷ Sign Up | |
| Japan | S5745200 | ANTI-INFLAMMATORY STEROID AND PHARMACOLOGICAL COMPOSITION CONTAINING THE SAME | ⤷ Sign Up |
| Italy | 8105186 | ⤷ Sign Up | |
| Portugal | 73348 | PROCESS FOR PREPARING SOFT STEROIDS HAVING ANTI-INFLAMMATORY ACTIVITY | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
